Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1.
doi: 10.1007/s11239-025-03141-y. Online ahead of print.

Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis

Andrea Tripoli  1 , Miguel A Samaniego  2 , Norma N Gamarra-Valverde  3 , Shivraj Paneer Selvam  4 , Edgardo Kaplinsky  5 , Alejandro Barbagelata  6   7 , Anna Mara Scandroglio  1 , Juliana Giorgi  8   9
Affiliations

Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis

Andrea Tripoli et al. J Thromb Thrombolysis. .

Abstract

Background: Vitamin K antagonists (VKAs) are the first-line strategy for anticoagulation in patients with left ventricular assist devices (LVADs). Recently, the HeartMate 3 (HM3) LVAD, has shown lower thrombotic complications than previous technologies. Direct oral anticoagulants (DOACs) are emerging as an alternative for oral anticoagulation in this patient cohort. However, their safety and efficacy remain uncertain. As DOACs represent a drug class with differing characteristics, this meta-analysis will examine the influence of the Direct Factor Xa inhibitor Apixaban on HM3-LVAD.

Methods: We systemically searched medical databases for studies comparing Apixaban and VKAs in patients supported with HM3. The primary outcome was hemocompatibility-related adverse events (HRAEs) and major bleeding. All-cause mortality, minor bleeding, all bleeding, thromboembolic events, and stroke were analyzed as secondary outcomes.

Results: Five studies involving a total of 209 patients (119 on Apixaban and 90 on VKAs) were included. The incidence of the primary safety outcome for major bleeding was significantly reduced in the Apixaban group (RR 0.21; 95% CI 0.05-0.81; p = 0.023; I²=0%). No statistically significant difference was found between Apixaban and VKA group in the analysis of the primary efficacy endpoint of HRAEs (RR 0.59; 95% CI 0.26-1.32; p = 0.204; I²=0%). All-cause bleeding was also significantly reduced (RR 0.33; 95% CI 0.19-0.57; p = 0.005, I²=0%).

Conclusions: This meta-analysis showed that Apixaban reduced bleeding complications, comparable stroke prevention, and similar survival outcomes. These findings suggest that Factor Xa inhibitors may provide a safer and more patient-friendly alternative to warfarin, particularly in reducing gastrointestinal bleeding and improving anticoagulation management adherence.

Keywords: Anticoagulation; Apixaban; Bleeding; Direct oral anticoagulants; Left ventricular assist device; Vitamin K antagonist.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Mehra MR, Goldstein DJ, Cleveland JC et al (2022) Five-Year outcomes in patients with fully magnetically levitated vs Axial-Flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 328(12):1233–1242. https://doi.org/10.1001/JAMA.2022.16197 - DOI - PubMed - PMC
    1. Schmitto JD, Shaw S, Garbade J et al (2024) Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. Eur Heart J 45(8):613–625. https://doi.org/10.1093/EURHEARTJ/EHAD658 - DOI - PubMed
    1. Meyer DM, Nayak A, Wood KL et al (2025) The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. Ann Thorac Surg.;119(1):34–58. https://doi.org/10.1016/J.ATHORACSUR.2024.10.003
    1. Martinez BK, Yik B, Tran R et al (2018) Meta-Analysis of time in therapeutic range in Continuous-Flow left ventricular assist device patients receiving warfarin. Artif Organs 42(7):700–704. https://doi.org/10.1111/AOR.13116 - DOI - PubMed
    1. Macaluso GP, Pagani FD, Slaughter MA et al (2022) Time in therapeutic range significantly impacts survival and adverse events in destination therapy patients. ASAIO J 68(1):14–20. https://doi.org/10.1097/MAT.0000000000001572 - DOI - PubMed

LinkOut - more resources